JPWO2019136358A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019136358A5 JPWO2019136358A5 JP2020537217A JP2020537217A JPWO2019136358A5 JP WO2019136358 A5 JPWO2019136358 A5 JP WO2019136358A5 JP 2020537217 A JP2020537217 A JP 2020537217A JP 2020537217 A JP2020537217 A JP 2020537217A JP WO2019136358 A5 JPWO2019136358 A5 JP WO2019136358A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- copper
- composition according
- containing agent
- ophthalmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 79
- 229910052802 copper Inorganic materials 0.000 claims 22
- 239000010949 copper Substances 0.000 claims 22
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 102000008186 Collagen Human genes 0.000 claims 8
- 108010035532 Collagen Proteins 0.000 claims 8
- 229920001436 collagen Polymers 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 6
- -1 depot Substances 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 239000006196 drop Substances 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 4
- 230000004515 progressive myopia Effects 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 2
- 102000004954 Biglycan Human genes 0.000 claims 2
- 108090001138 Biglycan Proteins 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims 2
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 claims 2
- 239000005750 Copper hydroxide Substances 0.000 claims 2
- 229910021594 Copper(II) fluoride Inorganic materials 0.000 claims 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 2
- 102000004237 Decorin Human genes 0.000 claims 2
- 108090000738 Decorin Proteins 0.000 claims 2
- 102000017177 Fibromodulin Human genes 0.000 claims 2
- 108010013996 Fibromodulin Proteins 0.000 claims 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 2
- 101710153980 Keratocan Proteins 0.000 claims 2
- 102100021497 Keratocan Human genes 0.000 claims 2
- 102100032114 Lumican Human genes 0.000 claims 2
- 108010076371 Lumican Proteins 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims 2
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- 229960000396 atropine Drugs 0.000 claims 2
- VUTNILBUSSZAIE-UHFFFAOYSA-N azane;sulfuric acid Chemical compound N.N.N.N.OS(O)(=O)=O VUTNILBUSSZAIE-UHFFFAOYSA-N 0.000 claims 2
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229940116318 copper carbonate Drugs 0.000 claims 2
- 229940108925 copper gluconate Drugs 0.000 claims 2
- 229910001956 copper hydroxide Inorganic materials 0.000 claims 2
- 229910000365 copper sulfate Inorganic materials 0.000 claims 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims 2
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 claims 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical group [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims 2
- GWFAVIIMQDUCRA-UHFFFAOYSA-L copper(ii) fluoride Chemical compound [F-].[F-].[Cu+2] GWFAVIIMQDUCRA-UHFFFAOYSA-L 0.000 claims 2
- YRNNKGFMTBWUGL-UHFFFAOYSA-L copper(ii) perchlorate Chemical compound [Cu+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O YRNNKGFMTBWUGL-UHFFFAOYSA-L 0.000 claims 2
- NZWIFMYRRCMYMN-ACMTZBLWSA-M copper;(2s)-6-amino-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoate Chemical compound [Cu+2].NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 NZWIFMYRRCMYMN-ACMTZBLWSA-M 0.000 claims 2
- RSJOBNMOMQFPKQ-UHFFFAOYSA-L copper;2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)C(O)C(O)C([O-])=O RSJOBNMOMQFPKQ-UHFFFAOYSA-L 0.000 claims 2
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 claims 2
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 claims 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims 2
- PEVJCYPAFCUXEZ-UHFFFAOYSA-J dicopper;phosphonato phosphate Chemical compound [Cu+2].[Cu+2].[O-]P([O-])(=O)OP([O-])([O-])=O PEVJCYPAFCUXEZ-UHFFFAOYSA-J 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000000017 hydrogel Substances 0.000 claims 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 239000002151 riboflavin Substances 0.000 claims 2
- 229960002477 riboflavin Drugs 0.000 claims 2
- 235000019192 riboflavin Nutrition 0.000 claims 2
- 125000001452 riboflavin group Chemical group 0.000 claims 2
- 229930187593 rose bengal Natural products 0.000 claims 2
- 229940081623 rose bengal Drugs 0.000 claims 2
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims 2
- IRPLSAGFWHCJIQ-UHFFFAOYSA-N selanylidenecopper Chemical compound [Se]=[Cu] IRPLSAGFWHCJIQ-UHFFFAOYSA-N 0.000 claims 2
- 239000004332 silver Substances 0.000 claims 2
- 229910052709 silver Inorganic materials 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 239000002562 thickening agent Substances 0.000 claims 2
- 239000012929 tonicity agent Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 235000012601 Euterpe oleracea Nutrition 0.000 claims 1
- 244000207620 Euterpe oleracea Species 0.000 claims 1
- 235000003650 acai Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 239000006195 ophthalmic dosage form Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 208000001491 myopia Diseases 0.000 description 4
- 230000004379 myopia Effects 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023123138A JP7655988B2 (ja) | 2018-01-05 | 2023-07-28 | 近視進行の治療 |
| JP2025046160A JP2025111434A (ja) | 2018-01-05 | 2025-03-21 | 近視進行の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614230P | 2018-01-05 | 2018-01-05 | |
| US62/614,230 | 2018-01-05 | ||
| PCT/US2019/012501 WO2019136358A1 (en) | 2018-01-05 | 2019-01-07 | Treatment of myopic progression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023123138A Division JP7655988B2 (ja) | 2018-01-05 | 2023-07-28 | 近視進行の治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021509902A JP2021509902A (ja) | 2021-04-08 |
| JP2021509902A5 JP2021509902A5 (https=) | 2022-01-18 |
| JPWO2019136358A5 true JPWO2019136358A5 (https=) | 2022-01-18 |
| JP7324208B2 JP7324208B2 (ja) | 2023-08-09 |
Family
ID=67143996
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537217A Active JP7324208B2 (ja) | 2018-01-05 | 2019-01-07 | 近視進行の治療 |
| JP2023123138A Active JP7655988B2 (ja) | 2018-01-05 | 2023-07-28 | 近視進行の治療 |
| JP2025046160A Pending JP2025111434A (ja) | 2018-01-05 | 2025-03-21 | 近視進行の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023123138A Active JP7655988B2 (ja) | 2018-01-05 | 2023-07-28 | 近視進行の治療 |
| JP2025046160A Pending JP2025111434A (ja) | 2018-01-05 | 2025-03-21 | 近視進行の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11524032B2 (https=) |
| EP (1) | EP3735209A4 (https=) |
| JP (3) | JP7324208B2 (https=) |
| KR (2) | KR20250109788A (https=) |
| CN (1) | CN112105320A (https=) |
| AU (2) | AU2019205774B2 (https=) |
| CA (1) | CA3087622A1 (https=) |
| WO (1) | WO2019136358A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11065275B2 (en) * | 2016-03-08 | 2021-07-20 | University Of Utah Research Foundation | Cross-linking agents and associated methods |
| KR20250109788A (ko) * | 2018-01-05 | 2025-07-17 | 유니버시티 오브 유타 리서치 파운데이션 | 근시 진행의 치료 |
| CA3146848A1 (en) * | 2019-07-11 | 2021-01-14 | University Of Utah Research Foundation | Multi-agent ocular formulations and treatment methods |
| TW202245810A (zh) * | 2021-02-01 | 2022-12-01 | 美商艾維娜傳送系統公司 | 散光之治療 |
| TW202302121A (zh) * | 2021-02-11 | 2023-01-16 | 猶他大學研究基金會 | 近視之治療 |
| CN115282349A (zh) * | 2022-07-05 | 2022-11-04 | 复旦大学附属眼耳鼻喉科医院 | 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂 |
| CN115386105B (zh) * | 2022-08-26 | 2024-03-22 | 昆明理工大学 | 多重酶活性纳米酶荧光水凝胶的制备方法及应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
| DE68913995T2 (de) | 1989-09-27 | 1994-08-25 | Mo Ni Skij I Glaznych Boleznej | Zusammensetzung zur behandlung progressiver myopie. |
| EP1159941A3 (en) * | 1991-10-15 | 2003-09-17 | Ista Pharmaceuticals, Inc. | Formulations for use in enzyme-orthokeratology |
| CN1047523C (zh) * | 1993-11-23 | 1999-12-22 | 华中理工大学 | 一种防治近视的滴眼液 |
| AU7488898A (en) | 1997-05-16 | 1998-12-08 | Corrective Vision, Inc. | Improved contact lens |
| BR9908692A (pt) * | 1998-03-09 | 2001-12-04 | Ista Pharmaceuticals Inc | Uso de agentes de enrijecimento corneal emortocerotologia enzimática |
| US6231889B1 (en) * | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
| CA2443244A1 (en) * | 2001-04-13 | 2002-10-24 | Incyte Genomics, Inc. | Enzymes |
| IL158904A0 (en) | 2001-05-25 | 2004-05-12 | Valley Forge Pharmaceuticals | Pirenzepine ophthalmic gel |
| NZ540885A (en) * | 2002-12-20 | 2009-02-28 | Chakshu Res Inc | Ophthalmic formulation for the prevention and treatment of ocular conditions |
| CN1518981A (zh) * | 2003-07-23 | 2004-08-11 | 复旦大学附属眼耳鼻喉科医院 | 一种治疗近视的外用滴眼制剂 |
| MXPA03011987A (es) * | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| WO2006055526A2 (en) | 2004-11-16 | 2006-05-26 | Nu-Tein Co., Inc. | Compositions useful to treat ocular neovascular diseases and macular degeneration |
| US20060276777A1 (en) * | 2005-04-08 | 2006-12-07 | Coroneo Minas T | Corneal shaping |
| US20080014278A1 (en) | 2006-06-30 | 2008-01-17 | Nucryst Pharmaceuticals | Metal-containing formulations and methods of use |
| WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| US20140343480A1 (en) * | 2013-05-19 | 2014-11-20 | Avedro, Inc. | Systems, methods, and compositions for cross-linking |
| RU2635185C2 (ru) * | 2013-12-17 | 2017-11-09 | Иван Дмитриевич Захаров | Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости |
| WO2015155117A1 (en) * | 2014-04-09 | 2015-10-15 | Universität Leipzig | A device for a medical treatment of a sclera |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| CN107530324A (zh) * | 2015-04-09 | 2018-01-02 | 雷伯瑞特里巴达西公司 | 用于眼科用途的吡咯烷酮羧酸（pca） |
| US10010502B2 (en) | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
| US11065275B2 (en) | 2016-03-08 | 2021-07-20 | University Of Utah Research Foundation | Cross-linking agents and associated methods |
| AU2018371787A1 (en) | 2017-11-21 | 2020-11-05 | Sydnexis, Inc. | Ophthalmic composition and delivery device thereof |
| KR20250109788A (ko) * | 2018-01-05 | 2025-07-17 | 유니버시티 오브 유타 리서치 파운데이션 | 근시 진행의 치료 |
| CA3146848A1 (en) * | 2019-07-11 | 2021-01-14 | University Of Utah Research Foundation | Multi-agent ocular formulations and treatment methods |
| TW202245810A (zh) * | 2021-02-01 | 2022-12-01 | 美商艾維娜傳送系統公司 | 散光之治療 |
| TW202302121A (zh) * | 2021-02-11 | 2023-01-16 | 猶他大學研究基金會 | 近視之治療 |
-
2019
- 2019-01-07 KR KR1020257022145A patent/KR20250109788A/ko active Pending
- 2019-01-07 WO PCT/US2019/012501 patent/WO2019136358A1/en not_active Ceased
- 2019-01-07 AU AU2019205774A patent/AU2019205774B2/en active Active
- 2019-01-07 CN CN201980014086.4A patent/CN112105320A/zh active Pending
- 2019-01-07 US US16/960,077 patent/US11524032B2/en active Active
- 2019-01-07 KR KR1020207022632A patent/KR102831250B1/ko active Active
- 2019-01-07 JP JP2020537217A patent/JP7324208B2/ja active Active
- 2019-01-07 EP EP19735793.2A patent/EP3735209A4/en active Pending
- 2019-01-07 CA CA3087622A patent/CA3087622A1/en active Pending
-
2022
- 2022-12-13 US US18/080,466 patent/US12544400B2/en active Active
-
2023
- 2023-07-28 JP JP2023123138A patent/JP7655988B2/ja active Active
-
2024
- 2024-12-06 AU AU2024278182A patent/AU2024278182A1/en active Pending
-
2025
- 2025-03-21 JP JP2025046160A patent/JP2025111434A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021509902A5 (https=) | ||
| JP2023103400A (ja) | 老視を治療するための組成物及び方法 | |
| JP6014033B2 (ja) | 防腐剤無添加ビマトプロストおよびチモロール溶液 | |
| JP2019524826A5 (https=) | ||
| CN115089547A (zh) | 人工泪液、隐形眼镜和药物载体组合物及其使用方法 | |
| US12544400B2 (en) | Treatment of myopic progression | |
| CA3010279A1 (en) | Compositions for the treatment of presbyopia | |
| JP2019508472A (ja) | 老視の処置のための組成物及び方法 | |
| JP2022511335A (ja) | 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法 | |
| TW202333700A (zh) | 用於治療眼病之組成物及方法 | |
| JPWO2019136358A5 (https=) | ||
| JPWO2020074697A5 (https=) | ||
| JP4968955B2 (ja) | 眼用薬物、ポロキサミンおよびグリコール張度調整剤を含有する眼用懸濁液、ならびに眼の障害を処置するための医薬の製造のためのこの組成物の使用 | |
| JP7629535B2 (ja) | 乱視の治療 | |
| JP2021534217A5 (https=) | ||
| Hamilton et al. | Filamentary keratitis | |
| WO2014138018A1 (en) | Preservative free bimatoprost and timolol solutions | |
| RU2019118904A (ru) | Распределение в глазу и фармакокинетика композиций лифитеграста | |
| MX2021006642A (es) | Compuestos y composiciones para tratamientos oculares. | |
| TW202317132A (zh) | 眼用組合物及/或用於老花眼、瞳孔放大及/或眼部不適管理之方法 | |
| CN118234482A (zh) | 近视的治疗 | |
| JPWO2021007578A5 (https=) | ||
| JPWO2022174094A5 (https=) | ||
| JPWO2020041340A5 (https=) | ||
| WO2024211322A2 (en) | Ripasudil based ophthalmic treatments |